AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2197428 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 0
Study 6112448 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose with pectin
Number of subjects: 12
Study 6112448 — intervention group
Group type: COMPARATOR
Intervention: Glucose alone
Number of subjects: 12
Study 31701186 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene educational intervention
Number of subjects: 717
Study 30055359 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)
Number of subjects: 89
Study 30055359 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous endoscopic lumbar discectomy (PELD)
Number of subjects: 89
Study 30055359 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PELD and MIS-TLIF
Number of subjects: 89
Study 27604363 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity recovery intervention using the SMART website alongside routine care
Number of subjects: 148
Study 27604363 — intervention group
Group type: COMPARATOR
Intervention: Befriending (comparison condition)
Number of subjects: 148
Study 24699062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusions (0.5 mg/kg over 40 minutes)
Number of subjects: 28
Study 24699062 — intervention group
Group type: EXPERIMENTAL
Intervention: Single infusion of ketamine (0.5 mg/kg)
Number of subjects: 28
Study 24699062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusions
Number of subjects: 28
Study 22149464 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) applied to abdomen-posterior back muscles, 5 days a week for 4 weeks, 30-minute sessions
Number of subjects: 32
Study 22149464 — intervention group
Group type: COMPARATOR
Intervention: Control group received only physical therapy and rehabilitation (PTR) for 4 weeks
Number of subjects: 32
Study 20798227 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthyroid subjects
Number of subjects: 5080
Study 20798227 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothyroid subjects
Number of subjects: 5080
Study 20798227 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with TSH<0.3 mIU/l
Number of subjects: 5080
Study 20798227 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with TSH>10 mIU/l
Number of subjects: 5080
Study 20798227 — intervention group
Group type: COMPARATOR
Intervention: Euthyroid subjects
Number of subjects: 5080
Study 20798227 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH levels
Number of subjects: 5080
Study 17700388 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg weekly
Number of subjects: 18
Study 17700388 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg weekly
Number of subjects: 18
Study 17700388 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg weekly
Number of subjects: 18
Study 17700388 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg every other week
Number of subjects: 18
Study 17700388 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg every other week
Number of subjects: 18
Study 16135896 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg QD
Number of subjects: 40
Study 16135896 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg BID
Number of subjects: 40
Study 16135896 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg QD
Number of subjects: 40
Study 16135896 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg BID
Number of subjects: 40
Study 16135896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11906322 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg thioctic acid
Number of subjects: 36
Study 11906322 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 600 mg
Number of subjects: 36
Study 11906322 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 36
Study 11906322 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 36
Study 9678312 — intervention group
Group type: EXPERIMENTAL
Intervention: Oculomotor testing (electro-oculography)
Number of subjects: 26
Study 8206687 — intervention group
Group type: EXPERIMENTAL
Intervention: poly(A).poly(U)
Number of subjects: 19
Study 2541740 — intervention group
Group type: EXPERIMENTAL
Intervention: Converting‐enzyme inhibitor (CEI)
Number of subjects: 77
Study 2541740 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 77
Study 4837835 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (3 sessions/week for 3 months)
Number of subjects: 26
Study 4837835 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no training)
Number of subjects: 26
Study 29551330 — intervention group
Group type: EXPERIMENTAL
Intervention: increase moderate to vigorous physical activity (MVPA) treatment group
Number of subjects: 204
Study 29551330 — intervention group
Group type: COMPARATOR
Intervention: decrease sedentary behavior control group
Number of subjects: 204
Study 28070018 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (2000 mg/day Longvida®; n=20)
Number of subjects: 39
Study 28070018 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=19)
Number of subjects: 39
Study 26202452 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training
Number of subjects: 304
Study 26202452 — intervention group
Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 304
Study 26202452 — intervention group
Group type: COMPARATOR
Intervention: Combined training
Number of subjects: 304
Study 23286591 — intervention group
Group type: EXPERIMENTAL
Intervention: TPB plus implementation intentions intervention
Number of subjects: 739
Study 23286591 — intervention group
Group type: EXPERIMENTAL
Intervention: TPB-only intervention
Number of subjects: 739
Study 21861995 — intervention group
Group type: EXPERIMENTAL
Intervention: IRIS (Iterative Reconstruction in Image Space)
Number of subjects: 90
Study 21861995 — intervention group
Group type: COMPARATOR
Intervention: IRIS in group B (100 kV/110 mAs)
Number of subjects: 90
Study 21861995 — intervention group
Group type: COMPARATOR
Intervention: IRIS in group C (120 kV/67 mAs)
Number of subjects: 90
Study 21861995 — intervention group
Group type: COMPARATOR
Intervention: FBP (Filtered Back-Projection) in group A (120 kV/110 mAs)
Number of subjects: 90
Study 19091804 — intervention group
Group type: EXPERIMENTAL
Intervention: PSST + PDA 8-week program
Number of subjects: 197
Study 19091804 — intervention group
Group type: COMPARATOR
Intervention: Traditional PSST 8-week program
Number of subjects: 197
Study 16680924 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5 or 10 mg)
Number of subjects: 21
Study 16680924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 15293489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis (AFO)
Number of subjects: 20
Study 11531751 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contrast computed tomography (NCCT)
Number of subjects: 224
Study 11531751 — intervention group
Group type: COMPARATOR
Intervention: Intravenous urography (IVU)
Number of subjects: 224
Study 9038591 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous insulin (50 m-units h-1 kg-1) for 4 hours
Number of subjects: 13
Study 9038591 — intervention group
Group type: COMPARATOR
Intervention: Control (8 subjects)
Number of subjects: 13
Study 8590112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, team-based case management program
Number of subjects: 40
Study 8590112 — intervention group
Group type: COMPARATOR
Intervention: Standard psychiatric services
Number of subjects: 40
Study 2766180 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from a nurse or physician (type of feedback)
Number of subjects: 175
Study 2766180 — intervention group
Group type: COMPARATOR
Intervention: Feedback (any type)
Number of subjects: 175
Study 1000140 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive therapy
Number of subjects: 0
Study 1000140 — intervention group
Group type: COMPARATOR
Intervention: Positive conditioning procedure
Number of subjects: 0
Study 30378448 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Tools And Rules for Teens intervention
Number of subjects: 35
Study 30378448 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 35
Study 29223441 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg once daily
Number of subjects: 800
Study 29223441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 24884948 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniscectomy surgery
Number of subjects: 40
Study 24884948 — intervention group
Group type: COMPARATOR
Intervention: Placebo surgery
Number of subjects: 40
Study 22699104 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage CIMT (6 hours/day for 21 days, total 126 hours)
Number of subjects: 18
Study 22699104 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dosage CIMT (3 hours/day for 21 days, total 63 hours)
Number of subjects: 18
Study 19727781 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration onto the neural root
Number of subjects: 51
Study 19727781 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bupivacaine infiltration)
Number of subjects: 51
Study 18541549 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein diet
Number of subjects: 162
Study 18541549 — intervention group
Group type: EXPERIMENTAL
Intervention: All 3 diets
Number of subjects: 162
Study 15836941 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 82
Study 15836941 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 82
Study 12088951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative small-dose ketamine (0.15 mg/kg followed by 2 microg. kg(‐1). min(‐1))
Number of subjects: 50
Study 12088951 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 50
Study 10334526 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 i.v. every 3 weeks (n=203)
Number of subjects: 392
Study 10334526 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin 12 mg/m2 i.v. every 6 weeks plus vinblastine 6 mg/m2 i.v. every 3 weeks (n=189)
Number of subjects: 392
Study 7604138 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline (2 x 30 mg)
Number of subjects: 112
Study 7604138 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 x 1)
Number of subjects: 112
Study 2122821 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN supplemented with alanyl‐glutamine
Number of subjects: 16
Study 2122821 — intervention group
Group type: COMPARATOR
Intervention: Conventional TPN without alanyl‐glutamine
Number of subjects: 16
Study 686848 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air plus machine‐produced cigarette smoke
Number of subjects: 20
Study 686848 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 20
Study 30449156 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walking test (6MWT)
Number of subjects: 0
Study 28121177 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic tape (Kinesio tape)
Number of subjects: 51
Study 28121177 — intervention group
Group type: COMPARATOR
Intervention: Placebo tape
Number of subjects: 51
Study 28121177 — intervention group
Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 51
Study 25911172 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 day bladder catheterisation
Number of subjects: 524
Study 25911172 — intervention group
Group type: COMPARATOR
Intervention: 14 day bladder catheterisation
Number of subjects: 524
Study 23547816 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 31
Study 21993319 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative CT scan
Number of subjects: 50
Study 21993319 — intervention group
Group type: COMPARATOR
Intervention: Intravenous urography and renal ultrasonography (no CT scan)
Number of subjects: 50
Study 19192084 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric mental health nursing interventions
Number of subjects: 25
Study 16239317 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild ovarian stimulation with GnRH antagonist co-treatment and transfer of one embryo
Number of subjects: 410
Study 16239317 — intervention group
Group type: COMPARATOR
Intervention: Conventional stimulation with GnRH agonist long protocol co-treatment and transfer of two embryos
Number of subjects: 410
Study 16239317 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild ovarian stimulation
Number of subjects: 410
Study 16239317 — intervention group
Group type: COMPARATOR
Intervention: Conventional stimulation
Number of subjects: 410
Study 15605332 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional tasks exercise program
Number of subjects: 24
Study 15605332 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise program
Number of subjects: 24
Study 11377349 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide (8 microg/kg)
Number of subjects: 30
Study 11377349 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (5 mg/kg)
Number of subjects: 30
Study 9005747 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg loading dose of warfarin
Number of subjects: 49
Study 9005747 — intervention group
Group type: COMPARATOR
Intervention: 5-mg loading dose of warfarin
Number of subjects: 49
Study 7984597 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 32
Study 7984597 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pulmonary tuberculosis
Number of subjects: 32
Study 3544286 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunochemotherapy using nimustine hydrochloride (ACNU) plus Picibanil (OK‐432) (group A)
Number of subjects: 51
Study 3544286 — intervention group
Group type: COMPARATOR
Intervention: Radiochemotherapy with ACNU only (group B)
Number of subjects: 51
Study 31754787 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-hour RA basic education program
Number of subjects: 0
Study 31754787 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-the-trainer training courses
Number of subjects: 0
Study 29898853 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 17160
Study 29898853 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 17160
Study 27978942 — intervention group
Group type: EXPERIMENTAL
Intervention: NOAC overdosing
Number of subjects: 5738
Study 27978942 — intervention group
Group type: EXPERIMENTAL
Intervention: NOAC underdosing
Number of subjects: 5738
Study 27978942 — intervention group
Group type: COMPARATOR
Intervention: Recommended NOAC doses
Number of subjects: 5738
Study 24456703 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF-eSET
Number of subjects: 116
Study 24456703 — intervention group
Group type: COMPARATOR
Intervention: IUI-ovarian stimulation
Number of subjects: 116
Study 22372543 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined superficial & deep fractional skin treatment using a 120‐micron, focused CO(2) laser beam
Number of subjects: 15
Study 22372543 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined superficial & deep fractional skin treatment
Number of subjects: 15
Study 21250576 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐step All Bond 3 (AB3‐2)
Number of subjects: 33
Study 21250576 — intervention group
Group type: COMPARATOR
Intervention: 3‐step All Bond 3 (AB3‐3)
Number of subjects: 33
Study 18418704 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental pulmonary vein isolation (group 1)
Number of subjects: 110
Study 18418704 — intervention group
Group type: COMPARATOR
Intervention: Circumferential pulmonary vein isolation (group 2)
Number of subjects: 110
Study 15708690 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.1 mg/day and salt 1 g/day
Number of subjects: 33
Study 15708690 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two capsules per day)
Number of subjects: 33
Study 14645018 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 12
Study 11053726 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV patients after weight loss
Number of subjects: 27
Study 11053726 — intervention group
Group type: COMPARATOR
Intervention: Lean controls
Number of subjects: 27
Study 8841834 — intervention group
Group type: EXPERIMENTAL
Intervention: niacinamide
Number of subjects: 72
Study 1737735 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intranasal midazolam (0.25 to 0.5 mg)
Number of subjects: 5
Study 1737735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 6390057 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 micrograms/kg to 100 micrograms/kg) + MPSS (30 mg/kg)
Number of subjects: 57
Study 6390057 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus doses of naloxone (30 micrograms/kg) + continuous infusion (30 micrograms/kg/hr for 1 hour) + MPSS (30 mg/kg)
Number of subjects: 57
Study 6390057 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (bolus and continuous infusion) without MPSS
Number of subjects: 57
Study 6390057 — intervention group
Group type: EXPERIMENTAL
Intervention: MPSS alone
Number of subjects: 57
Study 6390057 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 57
Study 6390057 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone and corticosteroids (MPSS)
Number of subjects: 57
Study 6390057 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose bolus and continuous infusion of naloxone + MPSS
Number of subjects: 57
Study 30950300 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-facilitated intervention
Number of subjects: 23
Study 30950300 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-listed)
Number of subjects: 23
Study 29100644 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score for prolonged hospital length of stay after heart transplantation
Number of subjects: 16723
Study 29100644 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model validation
Number of subjects: 16723
Study 27011266 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone 1 mg/kg/day, tapering by 5 mg/day, for 2 weeks
Number of subjects: 90
Study 27011266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapolyp steroid injection (40 mg/mL triamcinolone, 1 mL) for up to five times with intervals of 1 week
Number of subjects: 90
Study 24530944 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP levels at admission
Number of subjects: 794
Study 24530944 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP levels at 48-72 hours
Number of subjects: 794
Study 24530944 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP levels at 30 days
Number of subjects: 794
Study 24530944 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission hsCRP levels
Number of subjects: 794
Study 24530944 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher admission hsCRP levels
Number of subjects: 794
Study 24530944 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hsCRP at 30 days among survivors
Number of subjects: 794
Study 24530944 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP increase at day 30 (>10% increase over baseline)
Number of subjects: 794
Study 21947706 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg daily after EVL
Number of subjects: 43
Study 21947706 — intervention group
Group type: COMPARATOR
Intervention: No antisecretory treatment
Number of subjects: 43
Study 19411667 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine at a rate of 16.6 microg min(‐1) (concentration 1 microg ml(‐1))
Number of subjects: 70
Study 19411667 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine at a rate of 1.5 mg min(‐1) (concentration 90 microg ml(‐1))
Number of subjects: 70
Study 19411667 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Phenylephrine and Ephedrine)
Number of subjects: 70
Study 17311540 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 48
Study 17311540 — intervention group
Group type: COMPARATOR
Intervention: control group (C)
Number of subjects: 48
Study 15188371 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (100 mg/day loading dose for 3 days followed by 20 mg/day orally)
Number of subjects: 190
Study 15188371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 15188371 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 190
Study 11803993 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-delay curing with a waiting time of at least 1 minute between exposures
Number of subjects: 8
Study 11803993 — intervention group
Group type: COMPARATOR
Intervention: Continuous-cure control
Number of subjects: 8
Study 9930393 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy in addition to corticosteroid treatment
Number of subjects: 108
Study 9930393 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid treatment alone (Control)
Number of subjects: 108
Study 7850822 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase therapy
Number of subjects: 62
Study 7850822 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-plasminogen activator
Number of subjects: 62
Study 7850822 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (general)
Number of subjects: 62
Study 3362340 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline condition with letters presented in their upright orientation
Number of subjects: 0
Study 3362340 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotated +90 degrees condition
Number of subjects: 0
Study 3362340 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotated -90 degrees condition
Number of subjects: 0
Study 29848776 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitor (alogliptin)
Number of subjects: 0
Study 29848776 — intervention group
Group type: COMPARATOR
Intervention: Persistently high NT-proBNP
Number of subjects: 0
Study 29848776 — intervention group
Group type: COMPARATOR
Intervention: Developed high NT-proBNP at 6 months
Number of subjects: 0
Study 29848776 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP remained low at both time points
Number of subjects: 0
Study 29848776 — intervention group
Group type: COMPARATOR
Intervention: High NT-proBNP value at baseline that subsequently declined to low category
Number of subjects: 0